High fasting serum glucose in non-diabetic subjects ≥45 years is an indicator of future cardiovascular events as it is positively associated with atherogenic index of plasma

Archives of Physiology and Biochemistry

Volumn 118, Issue 2, 2012, Pages 43-46

  Sharma, Neha ^a   Baliarsingh, Simant ^a  

^a SRMS Institute of Medical Sciences   (India)

Author keywords

AIP index; Non diabetic; Serum glucose; Serum TG; Total cholesterol

Indexed keywords

LIPID;

ADULT; AGE; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGE FACTORS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; FASTING; HUMANS; LIPIDS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84860741275     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.3109/13813455.2012.677455     Document Type: Article

References (20)

1. Dobiasova M. (2004). Atherogenic Index of Plasma Log [(Triglycerides/HDL- Cholesterol)]: Theoretical and practical implications. Clin Chem 50(7):1113-1115. (Pubitemid 38824219)
2. DobiovM. (2006) AIP-atherogenic index of plasma-as a significant predictor of cardiovascular risk: From research to practice. Vnitr Lek 52(1):64-71.
3. Dobiasova M, Frohlich J. (2001) The plasma parameter log (TG/HDL-C) as an atherogenic index: Correlation with lipoprotein particle size and esterification rate in apo B-lipoprotein-depleted plasma (FERHDL). Clin Biochem 34(7):583-588. (Pubitemid 34014853)
4. Dobiavosa M, Urbanova Z, Samanek M. (2005) Relation between particle size of HDL and LDL lipoproteins and cholesterol esterification rate. Physiol Res 54(2):159-165. (Pubitemid 40686262)
5. Friedewald WT, Levy RI, Fredrickson DS. (1972). Estimation of the concentration of LDL cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem 18(6):499-502.
6. Geohas J, Daly A, Juturu V, Finch M, Komorowski JR. (2007). Chromium picolinate and biotin combination reduces atherogenic index of plasma in patients with type 2 diabetes mellitus: a placebocontrolled, double-blinded, randomized clinical trial. Am J Med Sci 333(3):145-153. (Pubitemid 47181613)
7. Hokanson JE, Austin MA. (1996) Plasma triglyceride level is a risk factor for cardio vascular disease independent of high density lipoprotein cholesterol level: A meta analysis of population based prospective studies. J Cardiovasc Risk 3(2):213-219. (Pubitemid 26266496)
8. Kvan E, Pettersen KI, Sandvik L, Reikval A. (2007). High mortality in diabetic patient with acute myocardial infarction: Cardiovascul arco-morbidities contribute most to the high risk. Int J Cardiol 121(2):184-188. (Pubitemid 47379453)
9. Levitan EB, Song Y, Ford ES, Liu S. (2004). Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 164(19):2147-2155. (Pubitemid 39410805)
10. McGee DL. (2005). Body mass index and mortality: A meta-analysis based on person-level data from twenty-six observational studies. Ann Epidemiol 15(2):87-97. (Pubitemid 40126638)
11. Mendis S, Puska P, Norrving B. (2011) Global atlas on cardiovascular disease prevention and control. Geneva: World Health Organization.
12. Norhammar A, Malmberg K, Diderhol E, Lagerqvist B, Lindahl B, Ryden L. (2004). Diabetes mellitus: The major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol 43(4):585-591. (Pubitemid 38229530)
13. Nwagha UI, Ikekpeazu EJ, Ejezie FE, Neboh EE, Maduka IC. (2010) Atherogenic index of plasma as useful predictor of cardiovascular risk among postmenopausal women in Enugu, Nigeria. Afr Health Sci 10(3):248-252.
14. Rao SS, Disraeli P, McGregor T. (2004). Impaired glucose tolerance and impaired fasting glucose. Am Fam Physician, 69(8):1961-1968.
15. Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, Mookadam F, Lopez-Jimenez F. (2006). Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 368(9536):666-678. (Pubitemid 44223694)
16. Sharma TK, Parchwani H, Kaushik GG, Shankar V, Dahiya K, Ghalaut VS, Sharma N. (2011). HbA(1c) levels in cardiovascular diseased patients without diabetes in a developing country. Clin Lab 57(7-8):517-522.
17. Tan MH, Johns D, Glazer NB. (2004) Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin Chem 50(7): 1184-1188. (Pubitemid 38824226)
18. Tan MH, Johns D, Strand J, Halse J, Madsbad S, Eriksson JW, Clausen J, Konkoy CS, Herz M. (2004). Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes. Diabet Med 21(8):859-866. (Pubitemid 39036999)
19. US Department of Health and Human Services. (2001). National Cholesterol Education Program [online]. Available at: http://www.nhlbi.nih.gov/guidelines/ cholesterol/atglance [Accessed 20 December 2012].
20. Yang D, Liu X, Xiang M. (2011). The correlation between lipids ratio and degree of coronary artery stenosis. High Blood Press Cardiovasc Prev18(2):53-56.